Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
Jyothi Thundimadathil Ph.D.
Jyothi Thundimadathil, Ph.D., is director of technical operations at CPC Scientific. Prior to that, he was a technical marketing associate at American Peptide Company.
More GEN Content From This Contributor
- Columns: 10 Tips for Designing Peptides
- Columns: Click Chemistry for Peptide Synthesis
- Feature Articles: Review: Glucagon-Like Peptide 1 (GLP-1) in the Treatment of Diabetes